IDEXX Laboratories Launches the SNAP® cPL™ Test to Screen for Pancreatitis in Dogs [Trade]
Rapid assay test provides easy, effective means to diagnose or help rule out pancreatitis in minutes

Westbrook, Maine, July 17, 2007—IDEXX Laboratories, Inc. (NASDAQ:IDXX), today announced the launch of the SNAP® cPL™ Test (canine pancreas-specific lipase), the first pet-side screening test developed to measure lipase enzyme levels specific to the pancreas and provide a more complete diagnostic picture in dogs presenting with vomiting, anorexia, abdominal pain and diarrhea (VAAD). This test helps veterinarians take an early step in targeting pancreatitis as a potential cause of illness during the patient visit.

“Knowing that pancreatitis has been difficult to diagnose in sick dogs due to nonspecific clinical signs and a lack of definitive diagnostics, we developed the SNAP cPL Test to provide accurate answers in minutes,” said Mike Sullivan, marketing director of the Canine Rapid Assay Division. “This test is the next generation of the popular IDEXX Reference Laboratories’ Spec cPL® Test, developed in collaboration with Drs. David Williams and Jörg Steiner, to offer the most sensitive and specific test available.”

The nonspecific symptoms of VAAD can just as easily signal a life-threatening illness—such as acute pancreatitis—as a minor condition. When dogs have abnormal results on the SNAP cPL Test, practitioners can quickly provide pet owners with answers and a plan for further diagnostics and/or treatment. Practices can then send out to IDEXX Reference Laboratories for a quantitative Spec cPL Test, which can help assess response to treatment and monitor a dog’s health after recovery. Therefore, the ability to diagnose or rule out acute pancreatitis at an early stage is an important enhancement to providing optimal patient care.

The new SNAP cPL Test uses ELISA technology for trusted accuracy. In just 10 minutes, the SNAP cPL Test provides a “normal” or “abnormal” result for pancreatic lipase levels.

For more information, go to www.idexx.com/snapcpl, or contact your local distributor or IDEXX Customer Support at 1-800-248-2483.

About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in companion animal health, serving practicing veterinarians around the world with innovative, technology-based offerings, including a broad range of diagnostic products and services, practice-management systems and pharmaceuticals. IDEXX’s products enhance the ability of veterinarians to provide advanced medical care and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 4,000 people and offers products to customers in over 100 countries.

Note Regarding Forward-Looking Statements
This press release contains statements about the Company’s business prospects and estimates of the Company’s financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management’s expectations. Factors that could cause or contribute to such differences include the following: the Company’s ability to develop, manufacture, introduce and market new products and enhancements to existing products; the impact of distributor purchasing decisions on sales of our products that are sold through distribution; changes or trends in veterinary medicine that affect the rate of use of the Company’s products and services by veterinarians; the Company’s ability to obtain and maintain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; and the Company’s ability to manufacture complex biologic products. A further description of these and other factors can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2006 (1.5 MB), and Form 10-Q for the quarter ended March 31, 2007 (272 KB), in the section captioned "Risk Factors."

This symbol indicates PDF-formatted materials. To view, you may need to download a free copy of Adobe^® Reader^® software.